Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimal serum potassium concentrations in heart failure: an individual patient data meta-analysis.

European heart journal·2026
Same author

[Physical Activity while wearing a Mask : A Comparison of Respiratory Parameters During Submaximal Exercise between Surgical, Cloth Masks and Sham Masks ; The PAM study].

Annales de cardiologie et d'angeiologie·2025
Same author

Progression of cardiac dysfunction in patients with type 2 diabetes without overt cardiovascular disease: A three-year follow-up echocardiographic study (DIACAR).

Diabetes, obesity & metabolism·2025
Same author

Ivabradine improves win ratios of heart failure outcomes in patients with reduced ejection fraction - insights from the SHIFT trial.

European journal of heart failure·2025
Same author

Prediction of 90 day mortality in elderly patients with acute HF from e-health records using artificial intelligence.

ESC heart failure·2025
Same author

Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial.

JACC. Heart failure·2025
Same journal

Response to "Beyond the aortic rim: Additional considerations in risk stratification for transcatheter atrial septal defect closure", a letter from Teruhiko Imamura commenting on the article entitled "Transcatheter closure of ostium secundum atrial septal defects in 2253 children and adults: Early outcomes" by Albenque et al.

Archives of cardiovascular diseases·2026
Same journal

Lessons learned during my collaboration with Alain Carpentier: A 25-year perspective.

Archives of cardiovascular diseases·2026
Same journal

Cardiac rhythm disorders in sickle cell disease: A literature review.

Archives of cardiovascular diseases·2026
Same journal

Evaluation of a multi-component intervention aimed at reducing time to treatment in transcatheter aortic valve implantation: Protocol for a cluster randomized controlled trial.

Archives of cardiovascular diseases·2026
Same journal

When angiography starts speaking the language of the myocardium.

Archives of cardiovascular diseases·2026
Same journal

Feasibility and safety of "fast-track" protocol after TAVI.

Archives of cardiovascular diseases·2026
See all related articles

Related Experiment Video

Updated: Jun 3, 2026

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
07:49

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models

Published on: July 21, 2023

Heart rate decrease: a new paradigm in the treatment of heart failure. Insights from the SHIFT study

Michel Komajda

    Archives of Cardiovascular Diseases
    |March 16, 2011
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
    12:45

    Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

    Published on: December 11, 2017

    Related Experiment Videos

    Last Updated: Jun 3, 2026

    A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models
    07:49

    A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models

    Published on: July 21, 2023

    Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
    12:45

    Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

    Published on: December 11, 2017